Another GLP1-RA, semaglutide, has been associated with a 266% (relative risk of 3.66) increased risk of VTE in a recent study, leading to concerns about its suitability for individuals at high risk of DVT.7 The gene discussed is GLP1R; the disease is deep vein thrombosis.